Experimental group:Almonertinib

A phase II study of Sacituzumab Tirumotecan combined with Almonertinib as first-line treatment for advanced NSCLC patients with high PD-L1 expression and EGFR mutations

Clinical study of ametinib as neoadjuvant therapy in EGFR positive patients with stage IIB to IIIA non-small cell lung cancer

Real-world protocol for first-line ematinib therapy in patients with locally advanced or metastatic NSCLC who are EGFR mutation-positive (21 L858R)